Pre-exposure prophylaxis (PrEP) is a medication regimen that is used to protect at-risk populations from HIV infection. The FDA approved the drug TRUVADA ...

A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...

The HIV epidemic remains a critical public health priority in the United States. The Ending the HIV Epidemic (EHE) initiative seeks to reduce HIV diagnoses by 75% by 2025 and by 90% by 2030. Certain ...

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...

Please provide your email address to receive an email when new articles are posted on . Survey results showed that transgender women and transfeminine nonbinary people support OTC PrEP. Lauren ...

Dr. Ruth Madievsky is terrified for her patients. As a clinical pharmacist who specializes in HIV care, she has watched the people she works with react in real time to the Trump administration’s ...

A new Canadian guideline on HIV prevention emphasizes the patient’s role in decisions related to pre-exposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) prescriptions. It also highlighted ...

Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...

Someone Hurley had recently had unprotected sex with had just tested positive for HIV. Hurley went to a clinic and got tested. “Luckily, I had not caught HIV, but it was a wake-up call,” they said.

The Rwanda Biomedical Center (RBC) said last week that the government plans to introduce lenacapavir, a long-acting injectable drug for HIV prevention, in the last quarter of the year. ALSO READ: ...